Skip to content

EBITDA at other companies

Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-$30.39M+28.0%
Immunome logo
ImmunomeIMNM
-$58.73M-33.4%
CG Oncology logo
CG OncologyCGON
-$65.55M-55.4%
Erasca, Inc. logo
Erasca, Inc.ERAS
-$187.19M-438%
Amgen logo
AmgenAMGN
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Calculated from Replimune Group’s reported figures.

$71.9Mebit+
$800.0KDepreciation Depletion & Amortization
=-$71.07M

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's EBITDA?
Replimune Group (REPL) reported EBITDA of -$71.07M in Q4 2025.
How has Replimune Group's EBITDA changed year-over-year?
Replimune Group's EBITDA decreased by 9.3% year-over-year, from -$65.02M to -$71.07M.
What is the long-term trend for Replimune Group's EBITDA?
Over 3 years (2022 to 2025), Replimune Group's EBITDA has grown at a 30.5% compound annual growth rate (CAGR), from -$116.17M to -$258.15M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.